GlassScriptPhysician profile
Andrew M Stevens
NPI 1679816078
$5,615.05
in general payments reported to CMS, 2019-2025
52 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $572 · 2021: $888 · 2022: $1,013 · 2023: $854 · 2024: $684 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,794.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $867.07 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Lilly USA, LLC | $619.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $400.53 | 2019-2025 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $368.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.78 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $268.29 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $264.72 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $182.36 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $179.71 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Verity Pharmaceuticals INC. | $155.03 | 2025 | Tlando |
| Pfizer INC. | $152.92 | 2021-2025 | |
| Boston Scientific Corporation | $143.80 | 2025 | General - Pain Management |
| Axsome Therapeutics, INC. | $124.72 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.80 | 2022-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $93.65 | 2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.